Skip to main content
Equibles
CSTL logo

CSTL · Castle Biosciences Inc · Metrics

Track CSTL — free

Use CSTL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CSTL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$33.08 -0.11 (-0.33%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$1.01B
Shares
30.55M
Volume · Oct 23 203.08K Avg daily vol (3M) 399.95K

CSTL metrics

98 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$33.08
Market cap
$1.01B

Price action

20 metrics
Price change (1W)
+3.5%
Price change (30D)
-7.6%
Price change (3M)
+34.0%
Price change (6M)
+35.2%
Price change (YTD)
-15.0%
Price change (1Y)
+36.8%
Trailing year
Price change (5Y)
-47.3%
52-week high
$43.04
52-week low
$18.15
Change from 52-week high
-23.1%
Change from 52-week low
+82.3%
Annualized volatility
57.2%
Annualized volatility (3M)
54.4%
Beta
0.9
RSI (14D)
47.5
Price vs SMA 50
-1.8%
Price vs SMA 200
+15.6%
Avg volume (3M)
399,945
Relative volume
0.5
Average dollar volume
$12.90M

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
30.55M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.1×
reciprocal yield 47.4%
EV / EBITDA
—
EV / EBIT
—
P / sales
2.8×
reciprocal yield 35.4%
P / book
2.2
reciprocal yield 46.5%
FCF yield
0.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
23.7
reciprocal yield 4.2%
Earnings yield
-1.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.6×
reciprocal yield 60.7%
EV / revenue historical average (5Y)
3.8×
reciprocal yield 26.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
37.3×
reciprocal yield 2.7%
EV / EBITDA historical average (5Y)
37.3×
reciprocal yield 2.7%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
77.3%
Operating margin
-9.0%
Trailing 12 months
Net margin
-5.4%
Gross profit (TTM)
$276.03M
Operating profit (TTM)
−$32.11M
Net income (TTM)
−$19.41M
Trailing 12 months
Diluted EPS (TTM)
$-0.64
FCF margin
-0.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$12.09
Gross profit per diluted share (TTM)
$9.34
Operating profit per diluted share (TTM)
$-1.08
EBITDA per diluted share (TTM)
$-0.56
Net income per diluted share (TTM)
$-0.65
Operating cash flow per diluted share (TTM)
$1.48
Free cash flow per diluted share (TTM)
$0.01
Capital expenditures per diluted share (TTM)
$1.46
R&D per diluted share (TTM)
$1.88
Stock compensation per diluted share (TTM)
$1.52
Book value per share
$15.86

Growth

11 metrics
Revenue growth YoY
+20.1%
Year over year
Net income growth YoY
-145.5%
Revenue (TTM)
$357.28M
Trailing 12 months
EPS growth YoY
-146.7%
Shares change YoY
+2.9%
Year over year · more shares
Revenue CAGR (3Y)
+35.9%
Revenue CAGR (5Y)
+40.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
+40.8%

Quality

14 metrics
Return on equity
-4.1%
Return on assets
-3.5%
Debt / equity
0.0
Current ratio
6.0
EBITDA (TTM)
−$16.52M
Free cash flow (TTM)
−$489,000
Quick ratio
5.8
Interest coverage
-85.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$256.73M
Latest balance sheet
Cash & equivalents
$62.12M
Total assets
$561.18M
Total debt
$10.07M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$42.63M
Capital expenditures (TTM)
$43.12M
R&D (TTM)
$55.45M
SG&A (TTM)
$243.66M
Stock compensation (TTM)
$44.87M
R&D / revenue
15.5%
Stock compensation / revenue
12.6%

Ownership (13F)

9 metrics
13F filers
177
13F filer change QoQ
-10
Institutional ownership
89.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
40.4%
Private-fund adviser ownership
34.2%
Active holders' share change QoQ
-2.1%
Holder tenure
11.8
Price vs estimated holder cost
-10.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.1%

Short interest

3 metrics
Short interest
6.5%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$8.78M
Insider-sentiment score
21 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1447362 CUSIP 14843C105 13F (30d) 24 filings 24 filers Visit website Investor relations